MXPA02009237A - Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma. - Google Patents
Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma.Info
- Publication number
- MXPA02009237A MXPA02009237A MXPA02009237A MXPA02009237A MXPA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A MX PA02009237 A MXPA02009237 A MX PA02009237A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- apomorphine
- plasma concentration
- sexual dysfunction
- concentration levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Se describe metodos para administrar apomorfina a un paciente para tratar disfunciones sexuales, al mismo tiempo que se reduce los efectos colaterales indeseables. En los metodos se alcanza una concentracion de apomorfina en el plasma del paciente hasta de 10 nanogramos por mililitro. Ventajosamente se puede obtener esta concentracion experimentando emesis menos del 15 por ciento de los pacientes asi tratados. Los metodos de administracion son intranasalmente, por inhalacion a los pulmones o por ingestion oral.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19054000P | 2000-03-20 | 2000-03-20 | |
PCT/US2001/040294 WO2001074358A1 (en) | 2000-03-20 | 2001-03-14 | Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02009237A true MXPA02009237A (es) | 2004-04-05 |
Family
ID=22701756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02009237A MXPA02009237A (es) | 2000-03-20 | 2001-03-14 | Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20020006933A1 (es) |
EP (1) | EP1265609A4 (es) |
JP (1) | JP2003533441A (es) |
KR (1) | KR20030012852A (es) |
CN (1) | CN1315177A (es) |
AU (1) | AU2001253854A1 (es) |
BG (1) | BG107185A (es) |
BR (1) | BR0005797A (es) |
CA (1) | CA2403791A1 (es) |
CZ (1) | CZ20023427A3 (es) |
HU (1) | HUP0301828A3 (es) |
IL (1) | IL151615A0 (es) |
MX (1) | MXPA02009237A (es) |
NO (1) | NO20024442L (es) |
PL (1) | PL365854A1 (es) |
SK (1) | SK15112002A3 (es) |
WO (1) | WO2001074358A1 (es) |
ZA (1) | ZA200207113B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
AR032556A1 (es) * | 2001-02-08 | 2003-11-12 | Pharmacia Corp | Medicamento de accion inmediata para el tratamiento de la disfuncion sexual |
EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
WO2004078211A1 (ja) * | 2003-03-04 | 2004-09-16 | Tanabe Seiyaku Co., Ltd. | 粉末経鼻投与製剤 |
CA2522231A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
GB0604319D0 (en) * | 2006-03-03 | 2006-04-12 | Optinose As | Nasal delivery |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
AU2011343429B2 (en) | 2010-12-16 | 2016-10-20 | Sunovion Pharmaceuticals Inc. | Sublingual films |
EP2545905A1 (en) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
ES2715028T3 (es) * | 2012-06-05 | 2019-05-31 | Neuroderm Ltd | Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos |
US20140377365A1 (en) * | 2013-06-19 | 2014-12-25 | Map Pharmaceuticals, Inc. | Sustained-release formulation of rotigotine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
DE4321965A1 (de) * | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen |
NZ504786A (en) * | 1997-12-02 | 2005-07-29 | West Pharm Serv Drug Res Ltd | Sustained release compositions for nasal administration of drugs for treating erectile disfunction and parkinson's disease |
US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
EP1089736A2 (en) * | 1998-06-22 | 2001-04-11 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
US6291471B1 (en) * | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
-
2000
- 2000-12-08 BR BR0005797-5A patent/BR0005797A/pt not_active Application Discontinuation
- 2000-12-20 CN CN00137440A patent/CN1315177A/zh active Pending
-
2001
- 2001-03-14 MX MXPA02009237A patent/MXPA02009237A/es unknown
- 2001-03-14 IL IL15161501A patent/IL151615A0/xx unknown
- 2001-03-14 CZ CZ20023427A patent/CZ20023427A3/cs unknown
- 2001-03-14 US US09/808,605 patent/US20020006933A1/en not_active Abandoned
- 2001-03-14 AU AU2001253854A patent/AU2001253854A1/en not_active Abandoned
- 2001-03-14 EP EP01927403A patent/EP1265609A4/en not_active Withdrawn
- 2001-03-14 JP JP2001572102A patent/JP2003533441A/ja active Pending
- 2001-03-14 SK SK1511-2002A patent/SK15112002A3/sk not_active Application Discontinuation
- 2001-03-14 HU HU0301828A patent/HUP0301828A3/hu unknown
- 2001-03-14 CA CA002403791A patent/CA2403791A1/en not_active Abandoned
- 2001-03-14 PL PL01365854A patent/PL365854A1/xx not_active Application Discontinuation
- 2001-03-14 WO PCT/US2001/040294 patent/WO2001074358A1/en not_active Application Discontinuation
- 2001-03-14 KR KR1020027012473A patent/KR20030012852A/ko not_active Application Discontinuation
-
2002
- 2002-09-04 ZA ZA200207113A patent/ZA200207113B/en unknown
- 2002-09-17 NO NO20024442A patent/NO20024442L/no not_active Application Discontinuation
- 2002-10-10 BG BG107185A patent/BG107185A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
EP1265609A4 (en) | 2005-02-09 |
CN1315177A (zh) | 2001-10-03 |
ZA200207113B (en) | 2004-01-28 |
CZ20023427A3 (cs) | 2003-11-12 |
SK15112002A3 (sk) | 2003-06-03 |
IL151615A0 (en) | 2003-04-10 |
KR20030012852A (ko) | 2003-02-12 |
BG107185A (bg) | 2003-05-30 |
EP1265609A1 (en) | 2002-12-18 |
CA2403791A1 (en) | 2001-10-11 |
AU2001253854A1 (en) | 2001-10-15 |
NO20024442L (no) | 2002-11-20 |
NO20024442D0 (no) | 2002-09-17 |
PL365854A1 (en) | 2005-01-10 |
BR0005797A (pt) | 2001-10-16 |
HUP0301828A2 (hu) | 2003-09-29 |
JP2003533441A (ja) | 2003-11-11 |
US20020006933A1 (en) | 2002-01-17 |
HUP0301828A3 (en) | 2006-02-28 |
WO2001074358A1 (en) | 2001-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02009237A (es) | Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma. | |
MXPA00007447A (es) | Tratamiento de disfuncion sexual femenina. | |
EP1201241A3 (en) | Compositions containing capsaicin or capsaicin analogues and a local anesthetic | |
IL145487A0 (en) | Apomorphine and sildenafil composition | |
AU6323001A (en) | Treatment of acute coronary syndrome with glp-1 | |
SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
BE2012C040I2 (es) | ||
WO2003079979A3 (en) | Method for treating congestive heart failure | |
HK1177901A1 (en) | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin 10--10- t | |
JP2002523370A5 (es) | ||
SI1646328T1 (sl) | Zdravljenje pri odvajanju od odvisnosti | |
MD1875G2 (ro) | Metodă de tratament al hepatitei virale acute B | |
IL159770A0 (en) | Calcium salts with cytotoxic activity | |
WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
UY27037A1 (es) | Composición de apomorfina para tratar la disfunción sexual con niveles específicos de concentración en plasma | |
WO2005097102A3 (en) | Method to treat chronic heart failure and/or elevated cholesterol levels | |
MXPA03000088A (es) | Herramienta de impacto con extremo de accionamiento desprendible. | |
AU8353601A (en) | Treatment of hepatitis c with thymosin, interferon and ribavirin | |
RU2006146071A (ru) | Средство для устранения фактора циркуляторной дисфункции | |
张地芬 | Observation on Treatment of Sciatica with Houding Acupoint | |
袁青 et al. | TREATMENT OF 284 CASES OF INFANTILE APHASIS CHIEFLY WITH | |
刘城林 et al. | A survey of researches on synergy and toxicity abatement of traditional Chinese medicine in radiotherapy of nasopharyngeal carcinoma | |
UA6738A (uk) | Спосіб лікування бронхообструктивного синдрому у хворих на бронхіальну астму та хронічний обструктивний бронхіт | |
UA30912A (uk) | Спосіб терапії хворих на хронічний обструктивний бронхіт | |
李兰敏 et al. | 58 Cases of Prostatic Hypertrophy Treated by Electroacupuncture |